Budesonide induces complete remission in autoimmune hepatitis

Table 1 Patients' characteristics

Patient (Gender/Age)	Diagnosis	IAHG Score	Autoantibodies (titer)				ALT (<0.85μmol/s.L)		ALP (<2.15μmol/s.L)		HAI		Fibrosis	Therapy	Res-
			ANA	SMA	ANCA	AMA							(Ref. 6)	(wk)	ponse
							pre-	post-	pre-	post-	pre-	post-
							Budesonide		Budesonide		Budesonide
First-line therapy
B.M-L. (F/65)	AIH-PBC	19	1280	-	-	-	15.18	0.22	7.12	1.44	5	3	3	241	CR
D.B. (M/26)	AIH	14	320	-	-	-	16.4	0.78	3.19	0.95	7	nd	4	36	CR
D.C. (F/49)	AIH	22	640	-	-	-	1.91	0.89	3.89	3.53	4	nd	5	24	NR/AE
H-S.M. (F/31)	AIH	17	160	80	-	-	4.43	0.6	1.62	0.9	7	nd	2	50	CR
K.M. (F/62)	AIH	14	-	-	-	-	3.45	3.59	7.86	6.29	5	nd	4	122	NR
L.M. (M/60)	AIH	16	640	640	-	-	4.1	0.35	nd	nd	1	nd	0	82	CR
N.G. (F/64)	AIH-PBC	12	2560	-	-	640	10.73	0.38	7.53	1.63	11	1	0	82	CR
S.T. (M/40)	AIH	12	-	-	>80	-	8.39	0.57	7.84	1.36	1	nd	0	24	CR
T.H. (F/50)	AIH	19	640	160	-	-	3.38	6.77	1.54	1.74	9	nd	3	42	NR
T.E. (F/49)	AIH-PBC	15	-	640	-	1280	2.27	0.58	4.21	1.61	5	2	5	112	CR
Second-line therapy
B.R. (M/39)	AIH	14	160	-	-	-	4.42	0.6	2.16	0.63	6	2	1	100	CR
B.S. (F/25)	AIH	17	160	-	-	-	16.48	0.41	4.89	1.38	6	1	3	116	CR
D.H. (F/61)	AIH-PBC	14	>2560	-	-	-3	2.37	0.45	11.91	1.24	5	3	4	32	CR
F.C. (F/41)	AIH	17	2560	2560	-	320	10.1	0.55	4.6	0.88	6	nd	2	72	CR
G.W. (M/68)	AIH-PBC	6	-	-	-	-	28.65	0.18	4.1	0.77	3	nd	4	110	CR
K.C. (F/40)	AIH	16	640	160	-	-	10.1	0.68	4.6	1.77	4	nd	1	50	CR
S.H-D. (M/64)	AIH-PSC	11	2560	-	-	-	2.01	0.6	30.13	2.3	4	1	1	80	CR
S.U. (F/41)	AIH-PSC	14	1280	-	-	-	20	0.3	5.1	1.65	6	nd	1	124	CR

CR = complete response; NR = no response; ANA = antinuclear antibodies; SMA = antibodies to smooth muscle; AMA = antimitochondrial antibodies; ANCA = antineutrophil cytoplasmic antibodies; 3 = anti-Sp100 positive; PSC = primary sclerosing cholangitis; PBC = primary biliary cirrhosis; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AE=adverse event; HAI = Hepatitis Activity Index; 1 = the therapy was continued with azathioprine; 2=discontinuation of the therapy because of no response;

Table 2 Patients receiving budesonide as second-line therapy

	Pre-budesonidetherapy PRD(mg/d)	AZA(mg/d)	URSO(mg/d)	Diagnosis	Side effects of PRD or AZA
Acute exacerbation of the disease
B.S.	0	100	0	AIH	no
D.H.	0	100	0	AIH-PBC	no
F.C.	0	100	0	AIH	no
G.W.	10	0	0	AIH-PBC	no
No response to PRD
S.H-D.	40	0	1000	AIH-PSC	Headache, hypertension
Side effects of the drugs
K.C.	10	100	0	AIH	Weight gain of 20 kg
B.R.	5	0	0	AIH	Osteoporosis, myopathy
S.U.	10	50	750	AIH-PSC	Pancreatitis